Proteins that are no longer needed, defective, or potentially harmful are labeled with a molecular "tag" and dismantled in ...

Enodia Therapeutics has raised €20.7m ($25m) in seed funding to advance a small-molecule platform for targeted protein ...

The startup is developing a medicine that can very specifically degrade cancerous forms of EGFR, the target of an array of ...

This article is based on a poster originally authored by Mat Calder, Ben Durham, Amy Prosser, Miguel Coelho, Aimee Blair, Jack Cobb, Marta Falcicchio, Ruben Alvarez Fernandez, Emma Ford, Alberto ...

The N-end rule pathway is a conserved proteolytic system that governs protein turnover by recognising specific destabilising residues at the N-terminus of substrates – so‐called N‐degrons. This ...

In the world of protein degradation, sometimes a spanner in the works isn’t an inconvenience but the desired result. Paris-based Enodia Therapeutics has launched out of France’s Pasteur Institute and ...

A collaboration led by CeMM, AITHYRA both in Vienna, Austria and the Max Planck Institute of Molecular Physiology in Dortmund ...

Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at ...

Therapeutics that leverage protein degradation as their primary mechanism of action appear to be a validated new therapeutic modality. The current clinical molecules are focused on degrading ...

A single damaged protein inside one brain cell may seem insignificant. Yet new research shows how that small mistake can ...